Last update 21 Nov 2024

Genistein

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4',5,7-trihydroxyisoflavone, 5,7,4'-trihydroxyisoflavone, 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one

+ [12]

Target

Top II x Tyrosine kinase

Mechanism

Top II inhibitors(Topoisomerase II inhibitors), Tyrosine kinase inhibitors, Apoptosis stimulants

Therapeutic Areas

NeoplasmsInfectious DiseasesRespiratory Diseases+ [3]

Active Indication

Lung InjuryPost Acute COVID 19 SyndromePulmonary Fibrosis+ [6]

Inactive Indication

Acute Radiation SyndromeAdenocarcinomaAdenocarcinoma of prostate+ [4]

Originator Organization

The Henry M. Jackson Foundation

Active Organization

Lawson Health Research Institute

Humanetics Corp.

National Institutes of Health

+ [1]

Inactive Organization

National Cancer InstituteXian Hengtai Herbal Technology Co. Ltd.

Uman Pharma, Inc.

+ [1]

Drug Highest PhasePhase 2

First Approval Date-

RegulationFast Track (US)

Structure

Molecular FormulaC15H10O5

InChIKeyTZBJGXHYKVUXJN-UHFFFAOYSA-N

CAS Registry446-72-0

Clinical Trials associated with Genistein

NCT06634108 / RecruitingPhase 1/2IIT

Cardiovascular Genistein Therapy for Heart Failure Inflammation

This Phase 1b/2a study aims to investigate the safety and efficacy of genistein in patients with Transthyretin (TTR) Amyloidosis. The focus is on its impact on inflammatory and cardiometabolic biomarkers, along with the effects on cardiac function and exercise capacity.
Blood samples will be collected at baseline, following each dose of genistein, and after a six-week placebo washout period. These samples will undergo extensive analyses, including profiling for inflammatory cytokines and novel molecular markers, and routine tests like CBC, Chem 7, LFT, HbA1c, NT-proBNP, CRP, troponin T, and serum TTR. RNA-seq analyses on peripheral blood mononuclear cells (PBMCs) and isolation of plasma exosomes for inflammatory biomarkers are also part of the protocol.
Following ESC/AHA guidelines, echocardiography will assess cardiac structure and function, focusing on the left and right ventricles and valvular function. Additionally, exercise capacity will be evaluated through a standardized 6-minute walk test, and NT-proBNP levels will be measured as a cardiac stress biomarker.
The trial will include an 18-week follow-up period post-enrolment, with the primary endpoint being the change in inflammatory markers from baseline to three months. Secondary endpoints are cardiac function and exercise capacity changes over the same timeframe. This study aims to provide significant insights into genistein's therapeutic potential for TTR Amyloidosis and its broader implications in managing heart failure.
Following ethical committee approval and written informed consent, the Investigators aim is to enroll 40 participants. This is an open-label study. Each patient will receive genistein by mouth: 250 mg twice a day for 4 weeks (500 mg total/day), 500 mg twice a day for 4 weeks (1000 mg total/day), and 750 mg twice a day (1500 mg total/day) for an additional 4 weeks. This will be followed by a 6-week washout period to conclude the study. An 18-month study is anticipated based on the average enrollment rates. Results from this study are expected to offer critical insights for future larger studies.

Start Date27 Sep 2024

Sponsor / Collaborator

Lawson Health Research Institute

[+1]

NCT06501768 / RecruitingPhase 1/2IIT

A Pilot Clinical Trial of Cardiovascular Genistein Therapy for Heart Failure Inflammation

This Phase 1b/2a open-label study is designed to assess the safety and efficacy of genistein in patients with heart failure (HF). The investigation will focus on its impact on inflammatory and cardiometabolic biomarkers, as well as its effects on cardiac function and exercise capacity.
Blood samples will be collected at baseline, following each administration of genistein, and after a six-week placebo washout period. These samples will be subjected to comprehensive analyses to evaluate inflammatory cytokines and novel molecular markers. Routine tests, including Complete Blood Count (CBC), Basic Metabolic Panel (Chem 7), Liver Function Tests (LFT), Hemoglobin A1c (HbA1c), N-terminal pro b-type natriuretic peptide (NT-proBNP), C-Reactive Protein (CRP), and troponin T will be performed. Advanced assessments will include RNA sequencing (RNA-seq) on peripheral blood mononuclear cells (PBMCs) and the isolation of plasma exosomes to identify inflammatory biomarkers. In addition, a subset of the blood samples will be used to generate induced pluripotent stem cells (iPSCs) to further explore the treatment's impact on heart failure-related inflammatory markers.
Echocardiography, in accordance with the European Society of Cardiology (ESC) and the American Heart Association (AHA) guidelines, will be utilized to evaluate cardiac structure and function with a specific focus on the left and right ventricular functions and valvular integrity. Exercise capacity will be gauged through a standardized six-minute walk test. Levels of NT-proBNP will be measured as an indicator of cardiac stress and function.
Participants will be followed up for 18 weeks post-enrolment, with the primary endpoint being the change in inflammatory markers from baseline to the three-month mark. Secondary endpoints will include changes in cardiac function and exercise capacity over the same period. The trial aims to enrol 40 participants, following ethical committee approval and the acquisition of written informed consent. Each patient will receive genistein at a dosing regimen starting with 250 mg twice daily (BID) for 4 weeks, escalating to 500 mg BID for the subsequent 4 weeks, and 750 mg BID for another 4 weeks, culminating in a 6-week follow-up period.
The insights garnered from this study are expected to be pivotal in guiding future larger-scale studies and to elucidate the therapeutic potential of genistein in the management of heart failure.

Start Date01 Jul 2024

Sponsor / Collaborator

UMC Ljubljana

[+1]

TCTR20220209010 / CompletedPhase 2/3IIT

Efficacy and safety of topical genistein nutraceutical products on skin in postmenopausal women

Start Date17 May 2022

Sponsor / Collaborator-

100 Clinical Results associated with Genistein

100 Translational Medicine associated with Genistein

100 Patents (Medical) associated with Genistein

12,092

Literatures (Medical) associated with Genistein

01 Feb 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Probing the interactions of genistein with HMGB1 through multi-spectroscopic and in-silico approaches

Article

Author: Kuang, Yi ; Yu, Boyang ; Ge, Haixia ; Ye, Junyi ; Zhang, Jian ; Shen, Pingping ; Raj, Richa

Functional regulation of proteins by ligand-protein interactions plays a crucial role in understanding biological processes and identifying potential drugs. High mobility group box 1 (HMGB1) plays a pivotal role in sterile inflammation as a key immunomodulatory protein. Genistein, a well-known isoflavone compound, has been shown to have neuroprotective effects. In this study, we investigated the genistein-HMGB1 interactions using experimental and computational approaches. Our results revealed that genistein binds to HMGB1 with a KD value of 6.06 × 10^-5 M. The addition of genistein significantly quenched the fluorescence of HMGB1. Thermodynamic analyses demonstrated that hydrogen bonds and hydrophobic forces are the primary forces during the binding process. Furthermore, the interaction between genistein and HMGB1 led to changes in the microenvironment of protein chromogenic amino acids and subtle alterations in the protein secondary structure. Molecular modeling results indicate that Pro95, Pro98, and Lys154 are the major amino acid residues for genistein binding to HMGB1. Meanwhile, at the cellular level, an inhibitory effect of genistein on HMGB1-induced NO release from microglia was observed, demonstrating an inhibition rate of 42.1 %. Our studies demonstrated that genistein could be applied in treating neurological diseases through its interaction with HMGB1.

01 Jan 2025·Brain Research

Therapeutic efficacy of Genistein in activation of neuronal AC/cAMP/CREB/PKA and mitochondrial ETC-Complex pathways in experimental model of autism: Evidence from CSF, blood plasma and brain analysis

Article

Author: Tiwari, Aarti ; Narula, Acharan S ; Mehan, Sidharth ; Sharma, Tarun ; Kumar, Manjeet ; Kumar, Aakash ; Narula, Acharan S. ; Das Gupta, Ghanshyam ; Khan, Zuber ; kumar, Manjeet

Autism is a complex neurodevelopmental condition characterized by repetitive behaviors, impaired social communication, and various associated conditions such as depression and anxiety. Its multifactorial etiology includes genetic, environmental, dietary, and gastrointestinal contributions. Pathologically, Autism is linked to mitochondrial dysfunction, oxidative stress, neuroinflammation, and neurotransmitter imbalances involving GABA, glutamate, dopamine, and oxytocin. Propionic acid (PRPA) is a short-chain fatty acid produced by gut bacteria, influencing central nervous system functions. Elevated PRPA levels can exacerbate Autism-related symptoms by disrupting metabolic processes and crossing the blood-brain barrier. Our research investigates the neuroprotective potential of Genistein (GNT), an isoflavone compound with known benefits in neuropsychiatric and neurodegenerative disorders, through modulation of the AC/cAMP/CREB/PKA signaling pathway and mitochondrial ETC complex (I-IV) function. In silico analyses revealed GNT's high affinity for these targets. Subsequent in vitro and in vivo experiments using a PRPA-induced rat model of autism demonstrated that GNT (40 and 80 mg/kg., orally) significantly improves locomotion, neuromuscular coordination, and cognitive functions in PRPA-treated rodents. Behavioral assessments showed reduced immobility in the forced swim test, enhanced Morris water maze performance, and restored regular locomotor activity. On a molecular level, GNT restored levels of key signaling molecules (AC, cAMP, CREB, PKA) and mitochondrial complexes (I-V), disrupted by PRPA exposure. Additionally, GNT reduced neuroinflammation and apoptosis, normalized neurotransmitter levels, and improved the complete blood count profile. Histopathological analyses confirmed that GNT ameliorated PRPA-induced brain injuries, restored normal brain morphology, reduced demyelination, and promoted neurogenesis. The study supports GNT's potential in autism treatment by modulating neural pathways, reducing inflammation, and restoring neurotransmitter balance.

01 Jan 2025·Journal of Ethnopharmacology

Qian Yang Yu Yin Granule prevents hypertensive cardiac remodeling by inhibiting NLRP3 inflammasome activation via Nrf2

Article

Author: Sun, Zeqi ; Fang, Zhuyuan ; Xu, Junyao ; Huang, Hong ; Liu, Ming ; Yuan, Fang ; Li, Yin ; Li, Jie

ETHNOPHARMACOLOGICAL RELEVANCEQian Yang Yu Yin Granule (QYYYG), a traditional Chinese poly-herbal formulation, has been validated in clinical trials to mitigate cardiac remodeling (CR), and cardiac damage in patients with hypertension. However, the specific mechanism remains unclear.AIM OF THE STUDYThis study explored the potential effects and potential mechanisms of QYYYG on hypertensive CR by combining various experimental approaches.MATERIALS AND METHODSSpontaneously hypertensive rats (SHRs) were used as a model of hypertensive CR, followed by QYYYG interventions. Blood pressure, cardiac function and structure, histopathological changes, and myocardial inflammation and oxidative stress were tested to assess the efficacy of QYYYG in SHRs. For in vitro experiments, a cell model of myocardial hypertrophy and injury was constructed with isoprenaline. Cardiomyocyte hypertrophy, oxidative stress, and death were examined after treatment with different concentrations of QYYYG, and transcriptomics analyses were performed to explore the underlying mechanism. Nrf2 and the ROS/NF-κB/NLRP3 inflammasome pathway were detected. Thereafter, ML385 and siRNAs were used to inhibit Nrf2 in cardiomyocytes, so as to verify whether QYYYG negatively regulates the NLRP3 inflammasome by targeting Nrf2, thereby ameliorating the associated phenotypes. Finally, high performance liquid chromatography (HPLC) was conducted to analyze the active ingredients in QYYYG, and molecular docking was utilized to preliminarily screen the compounds with modulatory effects on Nrf2 activities.RESULTSQYYYG improved blood pressure, cardiac function, and structural remodeling and attenuated myocardial inflammation, oxidative stress, and cell death in SHRs. The transcriptomics results showed that the inflammatory response might be crucial in pathological CR and that Nrf2, which potentially negatively regulates the process, was upregulated by QYYYG treatment. Furthermore, QYYYG indeed facilitated Nrf2 activation and negatively regulated the ROS/NF-κB/NLRP3 inflammasome pathway, therefore ameliorating the associated phenotypes. In vitro inhibition or knockdown of Nrf2 weakened or even reversed the repressive effect of QYYYG on ISO-induced inflammation, oxidative stress, pyroptosis, and the NLRP3 inflammasome activation. Based on the results of HPLC and molecular docking, 30 compounds, including cafestol, genistein, hesperetin, and formononetin, have binding sites to Keap1-Nrf2 protein and might affect the activity or stability of Nrf2.CONCLUSIONIn conclusion, the alleviatory effect of QYYYG on hypertensive CR is related to its regulation of Nrf2 activation. Specifically, QYYYG blocks the activation of the NLRP3 inflammasome by boosting Nrf2 signaling and depressing myocardial inflammation, oxidative stress, and pyroptosis, thereby effectively ameliorating hypertensive CR.

News (Medical) associated with Genistein

03 Oct 2024

·www.biospace.com

Humanetics Corporation Presents at the 2024 Department of Defense Scientific Meeting

Presentation to update the advanced development of BIO 300, an orally available medical countermeasure for Warfighters, to prevent toxicities due to radiation exposure. MINNEAPOLIS--(BUSINESS WIRE)--Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2024 Military Health System Research Symposium (MHSRS), held August 26-29 th in Kissimmee, Florida. MHSRS is the foremost scientific meeting of the U.S. Department of Defense (DOD), focusing on the unique medical needs of warfighters. BIO 300 was originally developed as a radioprotectant by researchers at the Armed Forces Radiobiology Research Institute (AFRRI) in Bethesda, Maryland. It was exclusively licensed to Humanetics for advanced development and commercialization. Collaborative studies continue with DOD scientists to develop BIO 300 as an oral drug that warfighters can take to provide protection against the effects of radiation from a radiological or nuclear event. Key Highlights of the Presentation: Novel Formulation: An overview of the BIO 300, an orally available drug designed for ease of use and rapid administration in various military and commercial settings. Efficacy and Safety: Insights into the nonclinical studies demonstrating the compound’s ability to protect against Acute Radiation Syndrome (ARS) and its safety in animal models. Clinical Development Pathway: An outline of clinical data supporting BIO 300’s safety and efficacy, including the proposed plan for human dose conversion under the FDA animal rule. Ongoing Development Activities: A detailed overview of ongoing and future development activities to support planned regulatory submissions. This work highlighted on BIO 300 research has positioned it as one of the most advanced prophylactic medical countermeasures currently under development for ARS. Developing countermeasures that protect individuals, especially military personnel, against ARS is paramount, considering the current geopolitical environment fueling the real and increasing threat of nuclear or radiological events. “We are thrilled to share our progress on the advanced development of BIO 300,” said Michael Kaytor, Ph.D., Vice President of Research and Development at Humanetics. “This drug could transform our ability to protect the men and women who serve our country, and anyone who may be at risk of intentional or accidental radiation exposure.” In addition to its military applications, BIO 300 is being evaluated in phase 2 clinical trials to prevent normal tissue injury resulting from cancer radiotherapy and to reduce inflammatory lung damage (e.g., COVID-19, Idiopathic Pulmonary Fibrosis, acute respiratory distress syndrome). The research presented was supported in part by grants from the US Department of Defense’s Congressionally Directed Medical Research Program and an Other Transaction Authority agreement with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND). The views expressed herein are those of Humanetics and may not reflect the official policy or position of the Department of Defense or the US Government. Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not constitute or imply its endorsement, recommendation, or favoring by the U.S. government and shall not be used for advertising or product endorsement purposes. About Humanetics Corporation Humanetics Corporation is a clinical-stage pharmaceutical company engaged in the accelerated discovery, development and commercialization of proprietary drugs in markets with urgent and unmet needs with a focus on radiation modulators for oncology and medical countermeasures. For more information, visit . Contacts Michael Kaytor VP – Research and Development mkaytor@humaneticscorp.com

Radiation TherapyPhase 2

01 Oct 2024

·www.biospace.com

Humanetics to Participate in the Bio Investor Forum in San Francisco

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, will discuss BIO 300, its promising lead radioprotective drug candidate, at the BIO Investor Forum, Oct. 15-16, 2024. This event showcases drug development programs ready for partnering or venture funding, focusing on accelerating new therapeutic technologies into commercialization. It features panel discussions on policy, business, financing, and R&D, along with company presentations and BIO One-on-One Partnering™ meetings. The 2023 forum hosted over 1,600 partnering meetings. The conference takes place at the Fairmont Hotel in San Francisco. For more information: . About BIO 300 BIO 300 is a pioneering radioprotectant drug with dual military and medical applications. It’s designed as a prophylactic to protect normal tissues from radiation damage, distinguishing it from other drug candidates. The U.S. Department of Defense (DoD) has heavily funded and researched BIO 300 for its potential to mitigate radiation effects on warfighters and civilians in the event of a nuclear attack or radiological incident. The need for such a product has significantly increased due to current world events. Humanetics is working under a $25 million DoD contract to position BIO 300 for Emergency Use Authorization against Acute Radiation Syndrome (ARS). BIO 300 is also being studied to improve outcomes in cancer patients receiving radiotherapy with or without chemotherapy. These patients often suffer from unintended side effects that can reduce treatment efficacy or cause serious adverse events. Administered as an oral liquid nanosuspension, it may minimize normal tissue radiation damage without compromising tumor treatment efficacy. Positive Phase 1/2a results in non-small cell lung cancer patients undergoing chemoradiotherapy support its safety and potential clinical benefits. A Phase 2b trial of BIO 300 in patients with post-acute respiratory complications from severe COVID-19 has been completed. This randomized, double-blind, placebo-controlled study evaluated BIO 300’s safety and efficacy in improving lung function. Funded by the National Institute of Allergy and Infectious Disease (NIAID), results are expected by late 2024. About Humanetics Corporation Humanetics is an advanced clinical-stage specialty pharmaceutical company engaged in the development and commercialization of radioprotectant drugs to prevent harm caused by exposure to ionizing radiation; for protective use in cancer radiation therapy; and to guard against the long-term damaging effects of COVID-19. For more information, visit . Contacts Jason Brown Director, Investor Relations jbrown@humaneticscorp.com (612) 868-7009

Radiation TherapyPhase 2

31 May 2024

·www.biospace.com

Humanetics Corporation to Present at the 2024 BIO International Convention in San Diego

MINNEAPOLIS--(BUSINESS WIRE)-- Humanetics Corporation, a clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and cancer patients, is presenting a corporate overview and details on its promising lead radioprotective drug candidate, BIO 300, at the prestigious Biotechnology Innovation Organization (BIO) International Convention in San Diego, CA next week. This convention, known for its global reach and influence, provides a platform for industry leaders to showcase their innovations. Ronald J. Zenk, Chief Executive Officer, will present this information on Monday, June 3, 2024 (1:30 pm Company Presentation Theatre 3). About BIO 300 Humanetics is pioneering the development of a groundbreaking radioprotectant drug, BIO 300. This innovative medical countermeasure, with its dual application in military and medical contexts, is designed to protect normal tissues from radiation damage, setting it apart from other drug candidates. BIO 300 has received considerable attention, funding, and research from the Department of Defense (DOD) for its potential to mitigate the harmful effects of radiation among warfighters and civilians in the event of a nuclear attack or radiological incident. The need for such a product has escalated significantly, given current world events. Humanetics is currently working under a contract with DOD to position BIO 300 for Emergency Use Authorization to provide the product to warfighters across the globe. BIO 300 is also indicated for use as a new class of drug to improve outcomes in cancer patients who received first-line radiotherapy with or without concurrent chemotherapy. These patients suffer from a myriad of unintended side effects, which can reduce the efficacy of treatment or result in serious toxicities. BIO 300 protects normal tissues, improving therapeutic outcomes. BIO 300 is currently undergoing phase 2 clinical trials, marking a significant milestone in its development journey. The trials aim to evaluate its effectiveness in preventing normal tissue injury from cancer radiotherapy and reducing lung damage in COVID-19 long-haul patients. Administered as an oral liquid nanosuspension, BIO 300 has shown promising potential to minimize radiation damage in normal tissues without compromising the effectiveness of radiation therapy against the tumor. These positive results from the Phase 1/2a clinical trial in non-small cell lung cancer patients undergoing chemoradiotherapy further bolster BIO 300’s prospects, indicating its safety and potential for positive clinical outcomes. About Humanetics Corporation Humanetics is an advanced clinical-stage specialty pharmaceutical company engaged in the development and commercialization of radioprotectant drugs to prevent harm caused by exposure to ionizing radiation; for protective use in cancer radiation therapy; and to guard against the long-term damaging effects of COVID-19. For more information, visit humaneticscorp.com. View source version on businesswire.com: Contacts Ronald J. Zenk Humanetics Corporation 952-400-0400 Source: Humanetics Corporation View this news release online at:

Radiation TherapyPhase 2

100 Deals associated with Genistein

External Link

KEGG	Wiki	ATC	Drug Bank
D11680	Genistein	-	DB01645

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 2	US	Humanetics Corp.	11 Nov 2020
Pulmonary Fibrosis	Phase 2	US	Humanetics Corp.	11 Nov 2020
Non-Muscle Invasive Bladder Neoplasms	Phase 2	US	National Institutes of Health	19 May 2017
COVID-19	Phase 2	-	Humanetics Corp.	-
Osteoporosis	Preclinical	CN	Xian Hengtai Herbal Technology Co. Ltd.	11 Apr 2017
Advanced Malignant Solid Neoplasm	Preclinical	CA	Uman Pharma, Inc.	01 Nov 2012
Non-Small Cell Lung Cancer	Preclinical	CA	Uman Pharma, Inc.	01 Nov 2012
Adenocarcinoma of prostate	Preclinical	US	National Cancer Institute	01 Dec 2011
Adenocarcinoma	Preclinical	SE	Axcentua Pharmaceuticals AB	01 Nov 2010
Breast Cancer	Preclinical	US	National Cancer Institute	01 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01489813 (CTgov)	Phase 2	Non-Muscle Invasive Bladder Neoplasms	36	sugar pill (Sugar Pill)	pdmxulolhm(jjyeyirrkr) = hmoelxeyaw wlflhkioin (vhxsqqoiww, usxlzbubjk - xyuyctbwmd) View more	-	25 Jul 2024
				Genistein (Genistein Supplement)	pdmxulolhm(jjyeyirrkr) = lvcdicjxhw wlflhkioin (vhxsqqoiww, gmudctwmkq - pxnkdbyygn) View more
EULAR2024	Not Applicable	Takayasu Arteritis	-	Genistein	egzmtvamrk(irfyjoimoh) = rosyveovxz gpwzydywcz (lwimynjrpe )	Positive	05 Jun 2024
NCT02624388 (UVA-Gen001, CTgov)	Phase 2	Hodgkin's Lymphoma \| Acute Lymphoblastic Leukemia \| Wilms Tumor \| Childhood Malignant Solid Neoplasm \| Rhabdomyosarcoma \| Ewing Sarcoma \| Soft Tissue Sarcoma \| Neuroblastoma \| Medulloblastoma \| pediatric lymphoblastic non-Hodgkin's lymphoma	4	Placebo+Genistein (Arm A: Genistein Followed by Placebo)	drvgtknbgh(fdjrbeyeol) = eftqfxlazm cybgtwvxae (bdwzkqtzsi, plhnhnrmov - ygwpspgoku) View more	-	06 May 2024
				Placebo+Genistein (Arm B: Placebo Followed by Genistein)	drvgtknbgh(fdjrbeyeol) = zkwdsvcdar cybgtwvxae (bdwzkqtzsi, dysvdakyfm - qhfuszmjmz) View more
NCT02567799 (Biospace) Manual	Phase 1/2	Non-Small Cell Lung Cancer	21	BIO 300	(bgtbrhhaff) = oulzsaguet obgwuhuwsp (iixldlivbl ) View more	Positive	19 Sep 2023
NCT02766478 (GeniPro, CTgov)	Phase 2	Metabolic Syndrome \| Prostatic Cancer	10	Genistein (Genistein)	lzzrpozijf(bnwboddely) = uuzkvoafyk jrgqmbmzoi (fumgmocyob, xcvwmkukxy - rgoeurnmmd) View more	-	27 Sep 2022
				Placebo (Placebo)	lzzrpozijf(bnwboddely) = xmxaybqhup jrgqmbmzoi (fumgmocyob, yutiksucme - iseirzcvap) View more
NCT04650555 (BusinessWire) Manual	Phase 1	-	34	BIO 300	mmcwqzrfcq(xlxkgaseqj) = increase survival in persons exposed to lethal levels of radiation uhogcmppbu (adjkqfrlsm )	Positive	22 Sep 2021
NCT01985763 (Pubmed \| Cancer Chemother Pharmacol) Manual	Phase 1/2	Metastatic Colorectal Carcinoma	13	FOLFOX+Bevacizumab+Genistein	(vthrtohemt) = 1patirent (grade 3 hypertension) rdmphilcpp (ljzmzekhnk ) View more	Positive	01 Sep 2019
NCT00287690 (CTgov)	Phase 2/3	Coronary Artery Disease	71	Genistein (Genistein)	czpcswhssu(clwwduzdby) = psiblnvcci pjwonfklbe (nbsnurgiil, pmnpdyxavs - oatqmplvsu) View more	-	05 Aug 2019
				Placebo (Placebo)	czpcswhssu(clwwduzdby) = huniuwjewn pjwonfklbe (nbsnurgiil, yrqcnsbzie - nsahhjqupp) View more
NCT01985763 (CTgov)	Phase 1/2	Rectal Cancer \| Colonic Cancer \| Metastatic Colorectal Carcinoma	13	Genistein	bihgrfjjvs(xzhochkkwi) = tzrkeaezbv xmxbfschpn (onrrortymr, qnsqfjpweo - rfslmpyuha) View more	-	10 May 2019
UEGW	Not Applicable	-	-	Genistein	bphwtsvegh(hqiysgogls) = nzwzwdaxls iicloqgcsm (ejppgdqpaz )	-	01 Oct 2018
				genistein (Control group)	nsvkmbzmph(kkoucwqpjc) = fuydsoitaw bwusmxefpq (yjkxsxmegx ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis